ILIAS Biologics ILIAS Therapeutics

(주)셀렉스라이프사이언스

Technology

ILIAS is the Leader of Next-Generation Exosome Therapeutics.

EXPLOR™ TECHNOLOGYEXPLOR™

EXPLOR™ (Exosome engineering for Protein loading
via Optically reversible Protein-Protein interaction)

Photoreceptor CRY2(Cryptochrome2) and CIBN(a truncated version of Cryptochrome Interacting Basic-Helix-Loop-Helix1) protein modules are originally
identified in Arabiodopsis thaliana. CRY2 and CIBN binds under blue light(450-490nm wavelength) illumination, not only in plant cells but also animal cells.

EXPLOR™ Technology is a drug loading platform technology, utilizing an aforementioned pair of protein modules. First, introduce two sets of genes
expressing CRY2-conjugated cargo protein and CIBN-conjugated exosome membrane-associated protein(ex, CD9) into cells. As these cells are incubated
under blue light, the cargo moves into the exosomes via optically induced CRY2-CIBN binding during the process of endogenous biogenesis. After the
secreted exosomes are purified by our isolation procedures, these are injected to patients in order to deliver the therapeutic cargo proteins to target cells.
The platform technology enables us to load large therapeutic proteins into the exosomes thereby we can stably deliver encapsulated cargo proteins to
target cells. This versatile platform technology is to develop innovative exosome-based bio medicines for various diseases with unmet need.

(Publication: Nature Communications, 2016 volume7, Article number: 12277)

Exo-Target®

Exo-Target® is the exosomes loaded with therapeutic cargo molecule(‘target’ molecule) via various technologies developed by ILIAS Biologics Inc.
ILIAS is developing numerous drugs and simultaneously conducting basic research with Exo-Target® loaded with therapeutic molecules including large proteins.

EXPLOR
Technology

Exo-Target

TOP

개인정보취급방침

닫기

이메일주소무단수집거부

닫기

사이트맵

사이트맵

몬트리올의정서
국내이행법령
사업안내
특정물질 수출입
알림·자료실
민원서비스
닫기